Abstract:Background: Pulmonary arterial hypertension (PAH) is a rare but severe and life-threatening condition that primarily affects the pulmonary blood vessels and the right ventricle of the heart. The limited availability of human tissue for research ~most of which represents only end-stage disease~ has led to a reliance on preclinical animal models. However, these models often fail to capture the heterogeneity and complexity of the human condition. Analyzing the molecular signatures in patient plasma provides a unique opportunity to gain insights into PAH pathobiology, explore disease heterogeneity absent in animal models, and identify potential therapeutic targets. Objective: This study aims to characterize the circulating peptides, metabolites, and lipids most relevant to PAH by leveraging unbiased mass spectrometry and advanced computational tools. Building on prior research that identified individual circulating factors, this work seeks to integrate these molecular layers to better understand their interactions and collective contribution to PAH pathobiology. Methods: Peripheral blood samples were collected from 402 patients with PAH and 76 healthy individuals. Various types of molecules in the blood ~ peptides, metabolites, and lipids ~ were measured. Statistical and machine learning methods were used to identify differences between PAH patients and healthy individuals, and further to understand how these molecules might interact with each other. A survival model was also trained to examine the association between the blood molecular signature and patient outcomes. Results: Differential abundance analysis revealed 832 peptides (from 291 proteins), 45 metabolites, and 222 lipids significantly altered in PAH compared to controls. Machine learning-based feature selection identified 11 key molecules, including 2~Hydroxyglutarate, that together achieved a classification accuracy of 98.6% for PAH in a multivariate model tested on a withheld cohort. Latent network discovery uncovered 7 distinct networks, highlighting interacting molecules from pathways ~such as hypoxia, glycolysis, fatty acid metabolism, and complement activation~ that we and others have previously linked to vascular lesions in PAH patients. A survival model incorporating 155 molecular features predicted outcomes in PAH patients with a c-index of 0.762, independent of traditional clinical parameters. This model stratified patients into risk categories consistent with established markers of cardiac function, exercise tolerance, and the REVEAL 2.0 risk score. Conclusion: This study underscores the utility of integrated omics in unraveling PAH pathobiology in human subjects. Our findings highlight the central role of hypoxia signaling pathways interacting with disrupted fatty acid metabolism, complement activation, inflammation, and mitochondrial dysfunction. These interactions, revealed through latent network analysis, emphasize the metabolic and immune dysregulation underlying PAH. Furthermore, many of the molecules identified in the circulation were consistent with pathways enriched in pulmonary vascular lesions, reinforcing their biological relevance. Circulating plasma molecules from these networks demonstrated strong prognostic capabilities, comparable to current clinical risk scores, offering insights into disease progression and potential for future clinical application.

The combination of supervised and unsupervised learning based risk stratification and phenotyping in pulmonary arterial hypertension-a long-term retrospective multicenter trial

Risk stratification and treatment goals in pulmonary arterial hypertension

Identification of candidate biomarkers and molecular networks associated with Pulmonary Arterial Hypertension using machine learning and plasma multi-Omics analysis

A claims‐based, machine‐learning algorithm to identify patients with pulmonary arterial hypertension

Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension

Improved Risk Prediction Using a Refined European Guidelines Instrument in Pulmonary Arterial Hypertension Related to Congenital Heart Disease

Risk stratification and medical therapy of pulmonary arterial hypertension

A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines

Abstract 15889: An Artificial Intelligence-Derived Pediatric Pulmonary Hypertension Risk Prediction Model From the Pediatric Pulmonary Hypertension Network (PPHNet) Registry

Identifying consistent echocardiographic thresholds for risk stratification in pulmonary arterial hypertension

Development of Predictive Risk Models for All-cause Mortality in Pulmonary Hypertension Using Machine Learning

Precision phenotyping from routine laboratory parameters for machine learning out-of-hospital survival prediction using 4D time-dependent SHAP plots in an all-comers prospective PCI registry

Phenotyping for percutaneous coronary intervention and long-term recurrent weighted outcomes

Identification of metabolic biomarkers in idiopathic pulmonary arterial hypertension using targeted metabolomics and bioinformatics analysis

Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment

Impact of left heart disease risk factors on risk stratification and treatment response in pulmonary arterial hypertension

Risk Assessment in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension: CSTAR-PAH Cohort Study.

Multiple Biomarkers Are Equivalent to Clinical Pulmonary Arterial Hypertension Survival Risk Models

Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype

Risk prediction in pulmonary hypertension due to chronic heart failure: incremental prognostic value of pulmonary hemodynamics

Assessing the precision of machine learning for diagnosing pulmonary arterial hypertension: a systematic review and meta-analysis of diagnostic accuracy studies